CR5 Stock Chart & Stats
€10.10
-€0.56(-5.86%)
At close: 4:00 PM EDT
€10.10
-€0.56(-5.86%)
Day’s Range― - ―
52-Week Range€7.22 - €29.30
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€459.50M
Enterprise Value€569.93M
Total Cash (Recent Filing)€8.00K
Total Debt (Recent Filing)€2.54M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 05, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding61,732,063
10 Day Avg. Volume20
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.51Price Target Upside221.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.38
Revenue Forecast (FY)€767.09K
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal leverage gives Oculis greater financial flexibility while it funds clinical development. The substantial equity and asset base can help support operations and reduce immediate balance-sheet pressure, although continued losses could erode this cushion over time.
Strong Liquidity BaseThe large cash and short-term financial asset position provides an important runway for a clinical-stage company with no meaningful product-sale revenue. It can support development programs and near-term obligations while reducing dependence on immediate external financing.
Pipeline Ownership ExpansionAcquiring full worldwide rights gives Oculis greater control over development, commercialization, and potential future economics for important pipeline assets. The transaction also aligns with its strategy to build a broader neuro-ophthalmology position and advance additional programs.
Bears Say
Shrinking Revenue And Deep LossesOculis remains far from a self-sustaining commercial model, with very limited and declining revenue alongside a large net loss. This indicates that clinical progress has not yet translated into meaningful operating income and leaves future performance dependent on pipeline execution.
Persistent Cash BurnSustained negative operating and free cash flow means Oculis consumes capital to fund its activities rather than generating cash internally. Continued burn can reduce its funding runway and increase the likelihood that future development will require additional financing or partnerships.
Accumulated Losses Pressure CapitalThe substantial accumulated deficit and negative return on equity show the long-term financial cost of Oculis’ development-stage model. If losses continue, the company’s equity cushion may gradually weaken, limiting flexibility even though current leverage remains very low.
Oculis Holding News
CR5 FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was €7.22 and its highest was €29.30 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is €459.50M.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Aug 06, 2026. The company reported -€0.171 earnings per share for the quarter, beating the consensus estimate of -€0.415 by €0.244.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.43.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 61,732,063 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -€0.171 in its last earnings report, beating expectations of -€0.415. Following the earnings report the stock price went up 1.97%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in DE:CR5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.51 (221.91% Upside)
€32.51 (221.91% Upside)
Blogger Sentiment
Bullish
DE:CR5 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.41%
12-Months-Change
Fundamentals
Return on Equity
-42.92%
Trailing 12-Months
Asset Growth
36.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oculis Holding
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
CR5 Stock 12 Month Forecast
Average Price Target
€32.51
▲(221.91% Upside)